SCHEMBL9997012

SCHEMBL9997012

Cc1ccc(Br)cc1S(=O)(=O)Nc1cccc(C(=O)O)c1O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
HSD17B10 Q99714 3/20 0.56
RPA1 P27694 2/20 0.56
GFER P55789 1/20 0.56
WDR5 P61964 7/20 0.55
KDM4E B2RXH2 2/20 0.53
POLB P06746 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MCL1 Q07820 2/20 0.51
BCL2L1 Q07817 1/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
PFKFB4 Q16877 1/20 0.48
METAP2 P50579 1/20 0.48
RAD52 P43351 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997386 0.79 ALDH1A1 (0.62) ALDH1A1HPGDHSD17B10GFERWDR5
SCHEMBL11665915 0.79 BRD4 (0.57) ALDH1A1HPGDHSD17B10RPA1GFER
SCHEMBL9997031 0.77 ALDH1A1 (0.73) ALDH1A1HPGDHSD17B10RPA1GFER
SCHEMBL9997964 0.76 FABP4 (0.60) ALDH1A1HPGDHSD17B10WDR5KDM4E
SCHEMBL11665908 0.76 BRD4 (0.57) ALDH1A1HPGDHSD17B10RPA1GFER
SCHEMBL2888830 0.76 KDM1A (0.54) ALDH1A1KDM4EPOLBMCL1BCL2L1
SCHEMBL30858466 0.74 KMT2A (0.53) ALDH1A1WDR5POLBKMT2AMEN1
SCHEMBL28637555 0.73 KMT2A (0.58) ALDH1A1HPGDHSD17B10KDM4EPOLB
SCHEMBL9997180 0.72 PTK2B (0.51) ALDH1A1HPGDHSD17B10MCL1BCL2L1
SCHEMBL13870868 0.72 RPA1 (1.00) ALDH1A1HPGDRPA1GFERKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed